Nobex Corporation (“Nobex” or the “Company”) a Debtor-In-Possession, is a development stage biopharmaceutical company with a proprietary drug delivery technology. The medicinal chemistry-based technology is applied to carefully selected human peptide hormones or small proteins to enable their efficient delivery by oral administration. The intellectual property portfolio built by the Company dominates the industry in the area of oral delivery of structurally modified peptide and protein drugs. The portfolio includes drugs for the treatment of diabetes, cardiovascular disease, osteoporosis, and inflammatory bowel disease among others.
Nobex was unable to attract additional investors willing to invest under its existing equity structure. After evaluating numerous strategic alternatives, management determined that the sale of the Company’s assets provided the most effective means to maximize value among shareholders.
SSG Capital Advisors, L.P. was retained as the exclusive investment banker regarding the sale of substantially all of the assets of Nobex Corporation. On January 28, 2006, proposed bidding procedures for the Nobex Section 363 sale process were approved by the Bankruptcy Court for the District of Delaware with Biocon Limited as the stalking horse buyer. After holding an auction for the assets of the Company in whole and in multiple parts and after spirited bidding, Nobex’s IP Portfolio in whole was sold to Biocon Limited of Bangalore, India. The transaction was approved by the Court on March 20, 2006 and closed on April 17, 2006.